Blogs about Biotechnology, Pharmaceutical and Healthcare

13:32 EDT 30th October 2014 | BioPortfolio

Read the latest opinions - blogs from pharmaceutical and life science industry experts.

Showing News Articles 1–25 of 62,000+

Thursday 30th October 2014

8 Stocks to Beat Warren Buffett's Portfolio Return Easily

Warren Buffett is one of the most trusted investors in the world. When he put money on the table, many institutional investors follow his moves and discover if they could make any money with the stocks he has chosen.[More...]

Analyzing the Commercial Biosimilar Landscape

The 15th annual Business of Biosimilars conference was a continuation of many of the market discussions that have previously surrounded the biologics and biosimilars landscape. Topics presented during the 2-day event included: assessing the commercial realities once biosimilars are approved in the US; emerging market assessment; naming conventions such as the recently proposed biological qualifier...

Late-in-life: As U.S 'spends more and gets less,' the Dutch offer myriad health and social supports

This article is part of a yearlong occasional series on late-in-life health care — when chronic illness or a constellation of medical problems can cause a cascade of new needs, complications and worries. The series is funded through a regrant by Allina Health from the Robina Foundation and is conducted with media partners Ampers and Twin Cities P...

York Hall Science Labs Get $6.5 Million Makeover to Help Students Graduate in Four Years

Four undergraduate teaching laboratories for biology and chemistry students have undergone a $6.5 million makeover as part of implementation of the UC San Diego Strategic Plan. The renovated labs in York Hall will eliminate a key barrier to students accessing impacted laboratory science courses—making it easier for them to graduate in four years.

California Brain Research Program Launched

Cal-BRAIN—a statewide research grants program that aims to revolutionize our understanding of the brain—is officially underway. The first call for proposals has gone out, and the program expects to announce its first awards in early 2015.

Aiming to Boost Innovation, Trinity Fine-Tunes Its Tech Transfer

Trinity College is Dublin’s most prestigious educational institution. Started over 400 years ago by Queen Elizabeth I, a number of the world’s best-known writers—Oscar Wilde, Samuel Beckett, and Bram Stoker, to name a few—are among it...

SurgaColl Aims to Fix Your Bones and Joints Without Drugs or Grafts

When you’ve got osteoarthritis in your knee or hip, there’s a good chance you may have to get that joint replaced—a costly procedure often followed by a lengthy stretch of rehab. Short of that, you may get some drugs to deal with the pain, ...

Chimerix Plans $105M Stock Offering to Finance Ebola Drug Trials

Antiviral drug developer Chimerix (NASDAQ: CMRX), which recently received the regulatory go-ahead to begin human tests of a potential Ebola drug, is launching a stock offering that could pay for those clinical trials. The Durham, NC company on Wednes...

Craft Beer and Coffee: The Rise of Dublin’s Innovation Culture

Seamus O’Hara made the career leap from life sciences venture capitalist to full-time craft beer brewer. A more lucrative industry? Perhaps. O’Hara’s brewery is in County Carlow, about an hour south of Dublin. He started the Carlow Brewing Comp...

Cigna's (CI) CEO David Cordani on Q3 2014 Results - Earnings Call Transcript

Update: Biotech Dyax Exceeds Q3 Estimates With The Future Looking Bright

When it comes to investing, the eye has it

This is a guest post by life sciences entrepreneur Mikael Totterman I was surprised by a recent Wall Street Journal article, which reported that venture capitalists are now investing more in the eyes than in any other organ. In 2013, VCs injected ...

Isis Pharmaceuticals, Inc. To Present At The

CARLSBAD, Calif., Oct. 30, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Nomura Biotechnology Conference on Thursday, November 6, 2014 at

Alphatec Spine To Showcase New Arsenal Spinal Fixation System At The Upcoming 29th Annual North American Spine Society Meeting In San Francisco

CARLSBAD, Calif., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a global provider of spinal fusion technologies, announced today that it will showcase its new spinal fixation system, Arsenal as well as its comprehensive portfolio...

Vical Incorporated Reports Third Quarter 2014 Financial Results And Progress In Key Development Programs

SAN DIEGO, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and nine months ended September 30, 2014. The net loss for the third quarter of 2014 was $4.4 million, or $0.05 per share, compared with a net loss of $9.9 million, or...

Ambit Biosciences Announces Expiration Of Hart-Scott-Rodino Waiting Period

SAN DIEGO, Oct. 28, 2014 /PRNewswire/ -- Ambit Biosciences Corporation (hereinafter, Ambit Biosciences) (NASDAQ: AMBI) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") in connection with Daiichi Sankyo's previously announced tender offer...

Neurocrine Biosciences, Inc. Receives Breakthrough Therapy Designation For NBI-98854 In Tardive Dyskinesia

SAN DIEGO, Oct. 30, 2014 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in tardive dyskinesia. A breakthrough therapy designation...

Immunomedics, Inc. Provides Update On Phase 2 Study Of Isactuzumab Govitecan In Patients With Diverse Metastatic Solid Cancers

SAN DIEGO, Oct. 29, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that isactuzumab govitecan (IMMU-132), the Company's proprietary solid-tumor antibody-drug conjugate (ADC), continues to produce encouraging results in a Phase 2 clinical trial in heavily...

EEG Test To Help Understand And Treat Schizophrenia, University of California, San Diego (UCSD) Study

Researchers at University of California, San Diego School of Medicine have validated an EEG test to study and treat schizophrenia. The findings, published in two separate studies, offer a clinical test that could be used to help diagnose persons at risk for developing mental illness later in life, as well as an approach for measuring the efficacies of different treatment options.One of...

Volcano Corporation Laying Off 170 Workers

San Diego-based medical device maker Volcano Corp. will be laying off 170 manufacturing employees in Rancho Cordova by Dec. 16.The move will bring the local employment for Volcano to fewer than 100 employees. At its peak, the company had nearly 700 employees at the local plant, which is at 2870 Kilgore Road.Volcano (NASDAQ: VOLC) is a developer and manufacturer of precision...

ImmunoGen: Analysis Of Earnings Miss

Update: Barrett Business Services Earnings Should Calm Pacific Health Care Organization Investors

What Lies Ahead for The Vaccine Industry?

We’ve got to ‘fight our corner’ was the massage from Novartis’ David McIntosh as he opened up the 2014 World Vaccine Congress Europe You opened the conference this morning with the claim that ‘we need to fight our corner’ in the vaccine industry. Is the vaccine industry in trouble?   The pharmaceutical industry is broadly […] The post What Lies Ahead for ...

Earnings Preview: Herbalife Q3 2014

Backed by Gates, Affinivax Ramps up Velcro-like Vaccine Tech

Prevnar 13 is a vaccine that, as its name suggests, protects against 13 of the most common strains of pneumococcal bacteria, which can cause deadly pneumonia and meningitis infections. There’s just one problem: there are around 90 total strains of ...

Search BioPortfolio: